Our previous studies showed that IGFBP3 is up-regulated after imatinib treatment in a responsive GIST cell line (GIST882), and we provide evidence that IGFBP3 does indeed partially mediate GIST882 cell response to imatinib in vitro. This evidence concerns the gene IGFBP3 and gastrointestinal stromal tumor.